| Dorinda Coleman, LCD | |
|
393 Central Ave, Newark, NJ 07103-2842 | |
| (973) 483-3444 | |
| (973) 485-7080 |
| Full Name | Dorinda Coleman |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 393 Central Ave, Newark, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033666144 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 37CA00046000 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dorinda Coleman, LCD 393 Central Ave, Newark, NJ 07103-2842 Ph: (973) 483-3444 | Dorinda Coleman, LCD 393 Central Ave, Newark, NJ 07103-2842 Ph: (973) 483-3444 |
News Archive
NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium.
NEXUS Biosystems, Inc. ("Nexus"), a leading innovator and worldwide provider of automated sample management systems, today announced the acquisition of Aurora Biotechnologies of Carlsbad, CA ("Aurora"), a leading developer of proprietary high performance microplates for use in sample storage, high-throughput screening, and cellular imaging.
Half of all American adults are destined to develop diabetes or pre-diabetes by 2020 if they don't make dramatic lifestyle changes, according to a dire new prediction from the Centers for Disease Control and Prevention.
The Center for One Health Illinois, established at the University of Illinois last year with a $250,000 grant from the U.S. Department of Agriculture, will receive another $500,000 in grants over several years from the USDA to pursue its mission of fostering collaborations and the free flow of information among those in the fields of medicine, public health, the environment and agriculture.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
› Verified 9 days ago
Janet Naranjo, Counselor Medicare: Not Enrolled in Medicare Practice Location: 183 S Orange Ave, Newark, NJ 07103 Phone: 800-969-5300 | |
Mr. Ariel Lippa,, LPC, LCADC, NCC. Counselor Medicare: Not Enrolled in Medicare Practice Location: 150 Bergen St, Newark, NJ 07103 Phone: 973-972-4300 | |
Joyce Travers-johnson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 183 South Orange Avenue, Newark, NJ 07103 Phone: 800-969-5300 | |
Jomaira Martinez, Counselor Medicare: Not Enrolled in Medicare Practice Location: 498 Ferry Street, Newark, NJ 07105 Phone: 718-725-9895 | |
Rosanna Dejesus, Counselor Medicare: Not Enrolled in Medicare Practice Location: 183 South Orange Avenue, Newark, NJ 07103 Phone: 800-969-5300 | |
Jesse Fields, Counselor Medicare: Not Enrolled in Medicare Practice Location: 183 South Orange Av, Newark, NJ 07103 Phone: 800-969-5300 | |
Dr. Viva L White, PHD,MSW,LCSW,LCADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 790 Clinton Ave, Newark, NJ 07108 Phone: 973-517-4488 Fax: 973-926-3577 |